iBio Inc
IBIO
查看详细走势图
2.420USD
+0.270+12.56%
收盘 02/06, 16:00（美东）报价延迟15分钟
49.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+12.56%
5天
+15.24%
1月
+11.52%
6月
+307.13%
今年开始到现在
+25.39%
1年
-34.95%
查看详细走势图
TradingKey iBio Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
iBio Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名95/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价4.52。中期看，股价处于上升通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
iBio Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
iBio Inc亮点
亮点风险
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
业绩增长期
公司处于发展阶段，最新年度总收入400.00K美元
估值低估
公司最新PE估值-1.73，处于3年历史低位
机构加仓
最新机构持股13.36M股，环比增加42.84%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值883.15K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.13
分析师目标
根据
5
位分析师
买入
评级
4.520
目标均价
+105.45%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
iBio Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
iBio Inc简介
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. Its pre-clinical pipeline of immuno-oncology targets the treatment of solid tumors, glioblastoma, head, and neck cancers. Its pipeline includes IBIO-101, TROP-2 x CD3, MUC16, EGFRvIII, CCR8, and Target 5. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.
公司代码IBIO
公司iBio Inc
CEOBrenner (Martin B)
网址https://ibioinc.com/
相关品种
